BridgeMD
New treatment option for Retinoblastoma, Extraocular
Official title Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
ClinicalTrials.gov ID: NCT04903678
What this study is testing
What is Melphalan?
Melphalan is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for retinoblastoma, extraocular.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Retinoblastoma is the most common intraocular malignancy in infancy and childhood. The overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- The pathological diagnosis was retinoblastoma. According to the IRSs (International retinoblastoma staging system) staging system, the stage was IVB
- CSF tumor cells on cytology, or radiographic evidence of NM on MRI scans and histologic diagnosis of systemic malignancy needed
- KPS≥60%
- Adequate bone marrow and organ function
- The parents signed the informed consent and were willing to accept the treatment and follow-up.
You likely can't join if
- 1.Eye diseases other than retinoblastoma
- The eyes were infected within 30 days before screening
- There was a history of surgery and / or unhealed wound within 1 month before enrollment .
- Those who have allergic reaction or allergic history to chemotherapeutic drugs.
- Infectious diseases requiring oral, intramuscular or intravenous administration.
- Patients with systemic immune diseases.
See the full eligibility criteria
- The pathological diagnosis was retinoblastoma. According to the IRSs (International retinoblastoma staging system) staging system, the stage was IVB
- CSF tumor cells on cytology, or radiographic evidence of NM on MRI scans and histologic diagnosis of systemic malignancy needed
- KPS≥60%
- Adequate bone marrow and organ function
- The parents signed the informed consent and were willing to accept the treatment and follow-up.
- 1.Eye diseases other than retinoblastoma
- The eyes were infected within 30 days before screening
- There was a history of surgery and / or unhealed wound within 1 month before enrollment .
- Those who have allergic reaction or allergic history to chemotherapeutic drugs.
- Infectious diseases requiring oral, intramuscular or intravenous administration.
- Patients with systemic immune diseases.
- Active disseminated intravascular coagulation.
- Abnormal coagulation function.
- Abnormal bone marrow and organ function.
- Uncontrollable clinical problems.
- The researchers believe that those who need to be excluded.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.